Trial Profile
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sellas Life Sciences Group
- 28 Mar 2024 Status changed from active, no longer recruiting to completed.
- 03 Jan 2024 According to a Sellas Life Sciences Group media release, data from this trial were presented at the International Gynecologic Cancer Society 2023 annual global meeting in November 2023.
- 17 Oct 2023 According to a Sellas Life Sciences Group media release, company is planning the submission of a full-length manuscript to a peer-reviewed journal during the first half of 2024.